GlassScriptPhysician profile
Kelli Coleman
NPI 1952864175
$5,152.65
in general payments reported to CMS, 2019-2025
16 companies · $1,278 in 2025
The $1,278 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $73.07 · 2021: $656 · 2022: $764 · 2023: $1,597 · 2024: $785 · 2025: $1,278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,659.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,573.67 | 2020-2025 | Hydrus Microstent, Clareon, Argos |
| New World Medical,INC. | $940.34 | 2023-2024 | Clearpath, Streamline, Ahmed Glaucoma Valve |
| Abbvie INC. | $570.26 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Biotissue Holdings INC. | $468.41 | 2024-2025 | |
| Sight Sciences, INC. | $369.48 | 2023-2025 | Omni Surgical System, Sion Surgical Instrument |
| Glaukos Corporation | $328.10 | 2022-2025 | Idosetr, Photrexa Viscous and Photrexa, Idose |
| Bausch & Lomb Americas INC. | $315.82 | 2022-2025 | Xiidra, Miebo, Envista Mx60 Iol |
| Dendreon Pharmaceuticals LLC | $126.80 | 2024 | Provenge |
| Allergan, INC. | $114.77 | 2020-2021 | |
| Oyster Point Pharma, INC. | $111.83 | 2025 | Tyrvaya, Ryzumvi |
| Horizon Therapeutics Plc | $64.94 | 2021 | |
| Dompe US, INC. | $55.91 | 2024-2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $55.46 | 2024-2025 | Acthar |
| Ocular Therapeutix, INC. | $21.49 | 2025 | Dextenza |
| Rayner Intraocular Lenses Limited | $18.96 | 2024 | Rayone Emv, Omidria, Rayone Aspheric |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $16.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelli Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.